US-China biotech investment tensions expose systemic techno-nationalism and global innovation fragmentation
Original framing: “Cross-border biotech deals grow more complex as US targets China investment links” — South China Morning Post
The US-China biotech rivalry echoes Cold War-era techno-nationalism, where scientific progress was weaponized for ideological competition. The 1980 Bayh-Dole Act in the US incentivized university-industry partnerships, later mirrored by China's 'Made in China 2025' plan, creating structural interdependence. The 2018 US CHIPS Act and China's 14th Five-Year Plan formalized this bifurcation, institutionalizing distrust.
The US-China biotech rivalry is not merely a geopolitical spat but a symptom of a deeper crisis in global innovation governance, where life-saving technologies are treated as pawns in a techno-nationalist chess game.
The historical arc of this tension traces back to the Cold War's militarization of science, but today's stakes are higher: climate change and pandemics demand collaboration, yet fragmentation is accelerating. Indigenous and Global South perspectives reveal alternatives rooted in stewardship and collective benefit, while corporate media obscures these voices to frame the conflict as inevitable. The solution pathways—neutral zones, decolonized governance, open-source models, and techno-diplomacy—offer not just fixes but a reimagining of biotech as a public good. The trickster's laughter reminds us that the absurdity of proprietary life is not a bug but a feature of a system that prioritizes control over care.